<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-161112" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Interpretation of Blood Clotting Studies and Values (PT, PTT, aPTT, INR, Anti-Factor Xa, D-Dimer)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zaidi</surname>
            <given-names>Syed Rafay H.</given-names>
          </name>
          <aff>Parkview Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rout</surname>
            <given-names>Preeti</given-names>
          </name>
          <aff>Wilson Case Western University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Syed Rafay Zaidi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Rout declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-161112.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Blood clotting studies play a crucial role in assessing the coagulation status of an individual, providing valuable insights into their risk of bleeding or thrombosis. Five commonly used tests for evaluating blood clotting are prothrombin time (PT), partial thromboplastin time (PTT), activated partial thromboplastin time (aPTT), international normalized ratio (INR), and anti-factor Xa levels. Interpreting the results of these tests requires a comprehensive understanding of the normal and abnormal values associated with each.<xref ref-type="bibr" rid="article-161112.r1">[1]</xref></p>
      </sec>
      <sec id="article-161112.s2" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Prothrombin Time</bold>
</p>
        <p>PT measures the time it takes for blood to clot, primarily assessing the extrinsic pathway of the coagulation cascade. Normal PT values range from 9 to 13 seconds. Higher PT values indicate a prolonged clotting time, suggesting potential issues with clotting factors such as fibrinogen, factor V, VII, X, and prothrombin. Abnormal PT values may indicate liver disease, vitamin K deficiency, or the presence of anticoagulants.<xref ref-type="bibr" rid="article-161112.r2">[2]</xref></p>
        <p>
<bold>Partial Thromboplastin Time</bold>
</p>
        <p>PTT, evaluates the intrinsic and common pathways of the coagulation cascade, assessing factors such as VIII, IX, XI, and XII, as well as fibrinogen. Normal PTT values range from 25 to 35 seconds. Prolonged PTT may signify deficiencies in these clotting factors, hemophilia, or the presence of inhibitors. Shortened PTT, on the other hand, may indicate an increased risk of thrombosis and could be associated with elevated factor VIII levels.</p>
        <p>
<bold>Activated Partial Thromboplastin Time</bold>
</p>
        <p>Similar to PTT, aPTT measures the same coagulation factors as PTT but with an activator added. Therefore, aPTT has a narrower range and may be more specific for certain conditions.<xref ref-type="bibr" rid="article-161112.r3">[3]</xref><xref ref-type="bibr" rid="article-161112.r4">[4]</xref></p>
        <p>
<bold>International Normalized Ratio</bold>
</p>
        <p>INR is a standardized measure of PT, ensuring consistency in results across different laboratories. The normal range for INR is around 0.8 to 1.2. Higher INR values suggest a slower clotting time and an increased risk of bleeding. INR is particularly crucial for individuals on oral anticoagulants like warfarin, where maintaining a target INR range is essential for balancing the risk of bleeding and clotting.</p>
        <p>
<bold>D-Dimer</bold>
</p>
        <p>D-dimer is a marker for fibrin degradation products, indicating ongoing fibrinolysis. Normal D-dimer values are typically less than 500 ng/mL. Elevated D-dimer levels may be observed in conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), or other conditions associated with increased fibrin turnover. However, D-dimer is not specific, and elevated levels can also be seen in inflammation, infection, surgery, or pregnancy.<xref ref-type="bibr" rid="article-161112.r5">[5]</xref></p>
        <p>
<bold>Clinical Significance</bold>
</p>
        <p>
<bold>Prothrombin Time</bold>
</p>
        <p>The clinical significance of prothrombin time lies in its utility for monitoring and managing anticoagulant therapy, assessing liver function, and diagnosing bleeding disorders.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Monitoring anticoagulant therapy:&#x000a0;</bold>PT is commonly used to monitor patients on oral anticoagulant therapy, such as warfarin. Warfarin interferes with the synthesis of certain clotting factors, including factor II (prothrombin), and monitoring PT helps ensure that the patient is within the therapeutic range. The INR is often reported along with PT results to standardize the interpretation of the test across different laboratories.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Assessing liver function:</bold> PT is also used to assess liver function since the liver produces many clotting factors. Liver diseases, such as cirrhosis, hepatitis, or liver failure, can decrease the synthesis of clotting factors, resulting in prolonged PT.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Diagnosing bleeding disorders: </bold>Prolonged PT can detect abnormalities in the clotting factors involved in the extrinsic and common pathways. This can help diagnose conditions such as hemophilia, vitamin K deficiency, or other inherited or acquired bleeding disorders.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Preoperative screening:&#x000a0;</bold>PT is sometimes used as part of preoperative screening to assess a patient's overall clotting ability. This helps identify individuals who may be at increased risk of bleeding during surgery.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Monitoring disseminated intravascular coagulation:&#x000a0;</bold>PT can be one of the parameters monitored in patients with DIC, a condition characterized by widespread activation of the clotting cascade. In DIC, both clotting factors and platelets are consumed, leading to abnormal bleeding and clotting at the same time.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Assessing vitamin K status:&#x000a0;</bold>Vitamin K is essential for the synthesis of certain clotting factors. PT can be used to assess vitamin K status, and prolonged PT may suggest a deficiency in this vitamin.</p>
          </list-item>
        </list>
        <p>
<bold>Partial Thromboplastin Time</bold>
</p>
        <p>PTT is often used with other tests, such as PT, to evaluate the overall coagulation function and monitor patients on anticoagulant therapy.<xref ref-type="bibr" rid="article-161112.r6">[6]</xref></p>
        <p>Here are some clinical significances of Partial Thromboplastin Time:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Assessment of hemostasis:&#x000a0;</bold>PTT helps assess the overall hemostatic function by evaluating the intrinsic coagulation pathway.&#x000a0;PTT provides information about the time it takes for a fibrin clot to form.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Monitoring anticoagulant therapy:&#x000a0;</bold>PTT is commonly used to monitor patients receiving heparin therapy. Heparin is an anticoagulant that primarily affects the intrinsic pathway. PTT measurements help ensure the patient is within the therapeutic range, preventing excessive bleeding and clot formation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Detection of coagulation disorders:&#x000a0;</bold>PTT is useful in identifying and evaluating various coagulation disorders, including hemophilia and other deficiencies in clotting factors of the intrinsic pathway.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Liver disease assessment: </bold>The liver&#x000a0;plays a crucial role in the synthesis of clotting factors. PTT and other coagulation tests may be used to assess liver function and detect liver diseases that affect coagulation factor synthesis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Preoperative screening:&#x000a0;</bold>PTT is often included in preoperative coagulation screening to identify patients who may be at risk of excessive bleeding during surgery.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Disseminated intravascular coagulation:&#x000a0;</bold>PTT is part of the panel of tests used to diagnose and monitor DIC, a serious condition where blood clotting and bleeding occur simultaneously throughout the body.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Evaluation of unexplained bleeding or thrombosis:&#x000a0;</bold>PTT can be part of the investigation when a patient presents with unexplained bleeding or thrombotic events, helping to identify underlying coagulation abnormalities.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Factor deficiencies:&#x000a0;</bold>PTT can help identify deficiencies or abnormalities in specific clotting factors within the intrinsic pathway, such as factor VIII deficiency (hemophilia A) or factor IX deficiency (hemophilia B).</p>
          </list-item>
        </list>
        <p>It's important to note that the PTT results should be interpreted in conjunction with clinical findings and other laboratory tests. Abnormal PTT results may indicate a need for further investigation and targeted therapies based on the underlying cause</p>
        <p>
<bold>International Normalized Ratio</bold>
</p>
        <p>The INR is widely used to monitor the effectiveness of anticoagulant medications, particularly warfarin, in patients with conditions such as atrial fibrillation, DVT, and PE. The clinical significance of INR lies in its role in managing and adjusting anticoagulant therapy to prevent both excessive bleeding and inadequate clotting.<xref ref-type="bibr" rid="article-161112.r7">[7]</xref></p>
        <p>Here are some key points regarding the clinical significance of INR:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Warfarin monitoring:</bold> INR is most commonly used to monitor patients taking warfarin. Warfarin works by inhibiting the synthesis of vitamin K-dependent clotting factors, and its dosage needs to be carefully adjusted to maintain a balance between preventing clot formation and avoiding excessive bleeding.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Thromboembolic risk reduction:</bold>&#x000a0;Anticoagulant therapy reduces the risk of blood clots in conditions such as atrial fibrillation, mechanical heart valves, and venous thromboembolism. INR monitoring ensures that the anticoagulant dose is within a therapeutic range, optimizing its efficacy in preventing thromboembolic events.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Target INR range:</bold> The target INR range varies depending on the specific medical condition. For example, patients with atrial fibrillation may have a target INR range of 2.0 to 3.0, while those with mechanical heart valves may require a higher range. Maintaining the INR within the target range is crucial for balancing bleeding and clotting risks.<xref ref-type="bibr" rid="article-161112.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Dose adjustment:</bold> If the INR is below the target range, the patient may be at risk for clot formation. In such cases, the physician may increase the anticoagulant dosage. Conversely, if the INR is above the target range, there is an increased risk of bleeding, and the dosage may be reduced or temporarily discontinued.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Regular monitoring:</bold> Patients on anticoagulant therapy require regular monitoring of their INR levels, especially when starting or changing medications or when changes occur in diet, lifestyle, or medication administration that could affect the anticoagulant's efficacy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Individual variability:</bold> Patients may respond differently to anticoagulant therapy, and individual variability in drug metabolism and other factors can influence the INR response. Regular monitoring helps to personalize treatment plans for optimal outcomes.</p>
          </list-item>
        </list>
        <p>In summary, the clinical significance of INR lies in its use as a tool for monitoring and adjusting anticoagulant therapy to prevent thromboembolic events while minimizing the risk of bleeding complications. Regular and careful monitoring of INR is essential for the safe and effective management of patients on anticoagulant medications.</p>
        <p>
<bold>D-Dimer</bold>
</p>
        <p>The clinical significance of D-dimer lies in its association with various medical conditions, particularly those related to thrombosis and coagulation. However, it is often nonspecific.<xref ref-type="bibr" rid="article-161112.r9">[9]</xref></p>
        <p>Here are some key points regarding the clinical significance of D-dimer:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Deep vein thrombosis and pulmonary embolism:&#x000a0;</bold>Elevated D-dimer levels are commonly seen in conditions associated with the formation and breakdown of blood clots, such as DVT (blood clots in deep veins) and PE (blood clots that travel to the lungs). D-dimer testing is often used to support the diagnosis of suspected DVT or PE. High levels of D-dimer may prompt further imaging studies, such as ultrasound or CT scans, to confirm the presence of blood clots. D-dimer's clinical use lies primarily in the fact that a negative test, along with low pretest probability, can exclude patients who are considered low-risk for clots.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Disseminated intravascular coagulation:&#x000a0;</bold>DIC is a serious condition where the blood clotting process is activated throughout the body, leading to widespread clot formation and consumption of clotting factors. This can result in bleeding complications. Elevated D-dimer levels are often seen in DIC, and D-dimer testing may be used to help diagnose and monitor this condition.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stroke and arterial thrombosis:&#x000a0;</bold>While D-dimer is more commonly associated with venous thrombosis, elevated levels may also be observed in certain arterial thrombotic events, such as stroke. D-dimer testing is not as specific for arterial events as it is for venous events, so its utility in assessing arterial thrombosis is limited.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Inflammatory and infectious conditions:&#x000a0;</bold>Elevated D-dimer levels can also be found in various inflammatory and infectious conditions, such as sepsis and certain autoimmune disorders. However, the specificity of D-dimer for these conditions is lower compared to its association with thrombotic events.</p>
          </list-item>
        </list>
        <p>
<bold>Anti-Factor Xa Levels</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Monitoring of&#x000a0;low molecular weight&#x000a0;heparin:&#x000a0;</bold>Anti-factor Xa levels are used to monitor low molecular weight heparin levels in the prevention and treatment of venous thromboembolism.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Special populations: </bold>Anti-factor Xa levels are<bold>&#x000a0;</bold>especially useful in cases of patients with obesity, patients with renal insufficiency, patients who are underweight, and pregnant patients to help ensure therapeutic levels.<xref ref-type="bibr" rid="article-161112.r10">[10]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Timing of level draws:</bold>&#x000a0;Levels should be checked 3 to 5 hours after the third dose to ensure accuracy of interpretation.<xref ref-type="bibr" rid="article-161112.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-161112.s3" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>When interpreting abnormal blood clotting study results, it's essential to consider the clinical context, medical history, and potential contributing factors. For example, a patient on anticoagulant therapy may have intentionally prolonged PT and INR values. Similarly, a patient with liver disease may exhibit abnormal PT and PTT due to impaired synthesis of clotting factors. Addressing abnormal values involves a multidisciplinary approach. In collaboration with other specialists, a hematologist can determine the underlying cause and develop a tailored treatment plan. This may include administering clotting factor concentrates, adjusting anticoagulant medications, or addressing the specific condition contributing to the abnormal clotting profile.</p>
        <p>Blood clotting studies provide valuable information about an individual's coagulation status, helping clinicians assess the risk of bleeding or thrombosis. Understanding the normal and abnormal values of PT, PTT, INR, and D-dimer is crucial for accurate interpretation and effective management of coagulation disorders. Regular monitoring and collaboration between healthcare professionals are key to ensuring optimal patient care and preventing complications associated with abnormal clotting.</p>
      </sec>
      <sec id="article-161112.s4">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=161112&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=161112">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/161112/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=161112">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-161112.s5">
        <title>References</title>
        <ref id="article-161112.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blennerhassett</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Favaloro</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pasalic</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Coagulation studies: achieving the right mix in a large laboratory network.</article-title>
            <source>Pathology</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>51</volume>
            <issue>7</issue>
            <fpage>718</fpage>
            <page-range>718-722</page-range>
            <pub-id pub-id-type="pmid">31668405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161112.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dorgalaleh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Favaloro</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Bahraini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rad</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Standardization of Prothrombin Time/International Normalized Ratio (PT/INR).</article-title>
            <source>Int J Lab Hematol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-28</page-range>
            <pub-id pub-id-type="pmid">32979036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161112.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feinbloom</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Freed</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Carbo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Adra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herzig</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Incidence and risk factors for PTT prolongation in patients receiving low-dose unfractionated heparin thromboprophylaxis.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>331</fpage>
            <page-range>331-337</page-range>
            <pub-id pub-id-type="pmid">33006065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161112.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toulon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Smahi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Pooter</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation.</article-title>
            <source>J Thromb Haemost</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>2002</fpage>
            <page-range>2002-2006</page-range>
            <pub-id pub-id-type="pmid">33555096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161112.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weitz</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Fredenburgh</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>A Test in Context: D-Dimer.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Nov</month>
            <day>07</day>
            <volume>70</volume>
            <issue>19</issue>
            <fpage>2411</fpage>
            <page-range>2411-2420</page-range>
            <pub-id pub-id-type="pmid">29096812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161112.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ignjatovic</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Activated partial thromboplastin time.</article-title>
            <source>Methods Mol Biol</source>
            <year>2013</year>
            <volume>992</volume>
            <fpage>111</fpage>
            <page-range>111-20</page-range>
            <pub-id pub-id-type="pmid">23546708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161112.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chornenki</surname>
                <given-names>NLJ</given-names>
              </name>
              <name>
                <surname>Fralick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sholzberg</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>International normalized ratio and activated partial thromboplastin time testing.</article-title>
            <source>CMAJ</source>
            <year>2022</year>
            <month>Aug</month>
            <day>29</day>
            <volume>194</volume>
            <issue>33</issue>
            <fpage>E1135</fpage>
            <pub-id pub-id-type="pmid">36302103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161112.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barcellona</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fenu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marongiu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Point-of-care testing INR: an overview.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>800</fpage>
            <page-range>800-805</page-range>
            <pub-id pub-id-type="pmid">27754958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161112.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robert-Ebadi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Righini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>D-dimer: Well beyond diagnosis!</article-title>
            <source>J Med Vasc</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>239</fpage>
            <page-range>239-240</page-range>
            <pub-id pub-id-type="pmid">32862979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161112.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sikes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Charles</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Antigua</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Imboywa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cherian</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Anti-Factor Xa Level Monitoring for Enoxaparin Prophylaxis and Treatment in High-Risk Patient Groups.</article-title>
            <source>HCA Healthc J Med</source>
            <year>2023</year>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-109</page-range>
            <pub-id pub-id-type="pmid">37424985</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
